✦ LIBER ✦

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

✍ Scribed by Faye M. Johnson; Lee M. Krug; Hai T. Tran; Stephanie Shoaf; Victor G. Prieto; Pheroze Tamboli; Beverly Peeples; Jyoti Patel; Bonnie S. Glisson

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 329 KB
Volume: 106
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21640

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly alternating therapy with irinotec

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

✍ William N. William Jr; James Uyeki; Faye M. Johnson; Lei Feng; Beverly O. Peeple 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Randomized Phase II study of two opposit

Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma

✍ Ji-Youn Han; Hyeong-Seok Lim; Dae Ho Lee; So Young Ju; Sung Young Lee; Hyae Youn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

## Abstract ## BACKGROUND Combined chemotherapy with irinotecan and cisplatin (IP) is active in patients with nonsmall cell lung carcinoma (NSCLC). However, the optimal administration schedule needs to be defined to maximize its synergic effect. The authors evaluated the efficacy, toxicity, and ph

Phase I study of carboplatin in combinat

Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors : Preliminary evidence of activity in small cell and neuroendocrine carcinomas

✍ Gilberto de Lima Lopes Jr.; Alberto Chiappori; George Simon; Eric Haura; Dan Sul 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

Phase 2 study of irinotecan and paclitax

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer

✍ Suresh S. Ramalingam; Judy Foster; William Gooding; Terry Evans; Matthew Sulecki 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

Phase II trial of irinotecan and cisplat

Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer

✍ Joo Hyuk Sohn; Yong Wha Moon; Chang Geol Lee; Gwi Eon Kim; Kyung Young Chung; Jo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 1 views

## Abstract ## BACKGROUND. A Phase II trial of irinotecan and cisplatin (IP) with early concurrent radiotherapy was performed in limited‐disease small‐cell lung cancer (LD‐SCLC) to evaluate the efficacy and toxicity. ## METHODS. For untreated LD‐SCLC patients, irinotecan (60 mg/m^2^, Days 1, 8,

A Phase II study of irinotecan in patien

A Phase II study of irinotecan in patients with advanced renal cell carcinoma

✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 2 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p